Therefore, DPP-4 inhibitors are a safe choice for the elderly and those with kidney disease, as they help control diabetes without the risk of causing further harm [7]
showed that T2DM patients being treated with tirzepatide revealed lower MASH-related biomarkers and an increase in adiponectin, a cytokine beneficial in the regulation of glucose levels, lipid metabolism, and insulin sensitivity [10, 45, 46]
Every patient receives an individualized evaluation to tailor the most beneficial treatment strategy aligned with personal health needs, insurance coverage, and preferences
Full receptor-coverage and evidence detail for each pick follows below
Another concern is that these ads promote the use of new drugs with safety profiles that are not fully known